Recent Advancements in Tuberculosis Drug Discovery

Tuberculosis is a major global health threat even today, claiming the lives of millions each year, despite the availability of effective treatments for the disease. The emergence of drug resistance and limitations of existing therapies demand the continuous development of new and improved drugs. This new book provides a comprehensive overview of the latest progress in this field, covering state-of-the-art approaches to untangle the complexities of drug resistance.

The book explores diagnosis methods, drug resistance mechanisms, and limitations in existing drugs and proposes strategies such as structural modifications, efflux pathway targeting, and host-directed therapies to overcome resistance. It also looks at artificial intelligence for TB management. Recent advancements in tuberculosis control, vaccine development, and biomarkers are also covered along with visions for the future of TB drug discovery, offering a glimpse into the evolving landscape of combating tuberculosis.

Vivek P. Chavda, MPharm, is currently working as an Assistant Professor in the Department of Pharmaceutics and Pharmaceutical Technology at the L. M. College of Pharmacy, Ahmedabad, Gujarat, India. Before joining academia, he served in the biologics industry for almost eight years in research and development with two successful regulatory filings at Lupin Biotech (Pune) and Dr. Reddys Laboratory (Hyderabad). He has more than 150 national and international publications, nearly 20 book chapters, several books, one patent in progress as well as numerous newsletter articles to his credit. His research interests include development of biologics processes and formulations, medical device development, nano-diagnostics, long-acting parenteral formulations, and nano-vaccines. He earned his BPharm and MPharm degrees (with gold medals) at Gujarat Technological University, Gujarat, India.

Mahesh T. Chhabria, PhD, is a Principal and Professor at the L. M. College of Pharmacy, Ahmedabad, Gujarat, India. He has around 68 research publications, one patent granted, and 10 patent applications to his credit. He has availed research grants of equating to nearly ＄1 million USD and has completed industrial research projects worth nearly ＄24,000 USD. He has also received grants for setting up of the Atal Incubation Centre at the L. M. College of Pharmacy. He is a recipient of CSR funds from industry worth equal to over ＄1.1 million USD as well. He has supervised around 135 MPharm students and 14 PhD students. He is a fellow of many scientific societies and has been awarded with a Hari Om Ashram Prerit Best Paper in Pharmacy award in the year 2006-07. His primary field of expertise revolves around medicinal chemistry and the utilization of computer-aided drug design methodologies. His research is primarily dedicated to the innovation and advancement of novel compounds targeting tuberculosis, hyperlipidemia, cancer, and COVID-19.

Divya M. Teli, MPharm, is an Assistant Professor in the Department of Pharmaceutical Chemistry at L. M. College of Pharmacy, Ahmedabad, Gujarat, India. She has industrial experience of five years in the Department of Research and Development at o2h discovery Pvt. Ltd. She has been serving as Assistant Professor at L. M. College of Pharmacy since 2018. Her area of interest includes synthesis of small organic heterocyclic molecules and indigenous novel route development for the synthesis of active pharmaceutical ingredients, key starting materials and drug intermediates, route scouting, computer aided-drug design, discovery and development of novel antitubercular, and anticancer and antiviral agents. She completed her bachelor and master degrees in Pharmacy at L. M. College of Pharmacy, affiliated with Gujarat Technological University, India.